[{"sentiment_polarity": "neutral", "is_about": true, "title": "Morgan Stanley", "entity_type": "Company", "evidence": 6, "themes": [{"stemmed": "transkaryotic therapy", "sentiment_polarity": "neutral", "is_about": false, "title": "Transkaryotic Therapies", "evidence": 7, "sentiment_score": 0.2365183, "normalized": "transkaryotic therapy", "strength_score": 2.0}, {"stemmed": "proprietary technology platform", "sentiment_polarity": "neutral", "is_about": false, "title": "proprietary technology platforms", "evidence": 4, "sentiment_score": 0.412779, "normalized": "proprietary technology platform", "strength_score": 1.5}, {"stemmed": "clinical product develop", "sentiment_polarity": "neutral", "is_about": false, "title": "clinical product development", "evidence": 4, "sentiment_score": 0.284662, "normalized": "clinical product develop", "strength_score": 1.5}, {"stemmed": "ipo file", "sentiment_polarity": "neutral", "is_about": false, "title": "IPO FILING", "evidence": 4, "sentiment_score": 0.048096158, "normalized": "ipo file", "strength_score": 1.0}, {"stemmed": "total share", "sentiment_polarity": "neutral", "is_about": false, "title": "Total shares", "evidence": 4, "sentiment_score": 0.18644089, "normalized": "total share", "strength_score": 1.0}], "confident": true, "sentiment_score": 0.23255579, "label": "Company", "type": "named"}, {"sentiment_polarity": "neutral", "is_about": true, "title": "Hoechst Marion Roussel Inc", "entity_type": "Company", "evidence": 6, "themes": [{"stemmed": "transkaryotic therapy", "sentiment_polarity": "neutral", "is_about": false, "title": "Transkaryotic Therapies", "evidence": 7, "sentiment_score": 0.2365183, "normalized": "transkaryotic therapy", "strength_score": 2.0}, {"stemmed": "proprietary technology platform", "sentiment_polarity": "neutral", "is_about": false, "title": "proprietary technology platforms", "evidence": 4, "sentiment_score": 0.412779, "normalized": "proprietary technology platform", "strength_score": 1.5}, {"stemmed": "clinical product develop", "sentiment_polarity": "neutral", "is_about": false, "title": "clinical product development", "evidence": 4, "sentiment_score": 0.284662, "normalized": "clinical product develop", "strength_score": 1.5}, {"stemmed": "ipo file", "sentiment_polarity": "neutral", "is_about": false, "title": "IPO FILING", "evidence": 4, "sentiment_score": 0.048096158, "normalized": "ipo file", "strength_score": 1.0}, {"stemmed": "total share", "sentiment_polarity": "neutral", "is_about": false, "title": "Total shares", "evidence": 4, "sentiment_score": 0.18644089, "normalized": "total share", "strength_score": 1.0}], "confident": true, "sentiment_score": 0.23255579, "label": "Company", "type": "named"}, {"sentiment_polarity": "neutral", "is_about": false, "title": "Transkaryotic Therapies Inc", "entity_type": "Company", "evidence": 1, "themes": [{"stemmed": "transkaryotic therapy", "sentiment_polarity": "neutral", "is_about": false, "title": "Transkaryotic Therapies", "evidence": 7, "sentiment_score": 0.26162526, "normalized": "transkaryotic therapy", "strength_score": 2.0}, {"stemmed": "proprietary technology platform", "sentiment_polarity": "neutral", "is_about": false, "title": "proprietary technology platforms", "evidence": 4, "sentiment_score": 0.412779, "normalized": "proprietary technology platform", "strength_score": 1.5}, {"stemmed": "ipo file", "sentiment_polarity": "neutral", "is_about": false, "title": "IPO FILING", "evidence": 4, "sentiment_score": 0.058138948, "normalized": "ipo file", "strength_score": 1.0}, {"stemmed": "total share", "sentiment_polarity": "neutral", "is_about": false, "title": "Total shares", "evidence": 4, "sentiment_score": 0.18895158, "normalized": "total share", "strength_score": 1.0}, {"stemmed": "lead underwriter", "sentiment_polarity": "neutral", "is_about": false, "title": "Lead Underwriter", "evidence": 4, "sentiment_score": 0.21075368, "normalized": "lead underwriter", "strength_score": 1.0}], "confident": true, "sentiment_score": 0.0, "label": "Company", "type": "named"}]